Drug Industry CEOs Are Taking “Positive” Steps On GMPs, FDA’s Galson Says
This article was originally published in The Tan Sheet
Executive Summary
FDA's discussions with pharmaceutical industry CEOs over the past year give the agency confidence that manufacturing quality is improving, Center for Drug Evaluation & Research Deputy Director Steven Galson, MD, told the Schwab Washington Research Group conference May 2
You may also be interested in...
FDA PAT Inspection Teams Being Formed: Further Training Set For Fall
FDA is assembling review/inspection teams to help evaluate upcoming industry submissions involving implementation of process analytical technologies in manufacturing
FDA/Industry Manufacturing Approach Is “Suboptimal” – CDER’s Woodcock
FDA is ready to change the current model of manufacturing oversight and enforcement, Center for Drug Evaluation & Research Director Janet Woodcock, MD, indicated during the recent Lehman Brothers Global Healthcare Conference in Orlando
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC